About the Company

GeNeuro (EPA: GNRO.PA) is a Swiss pharmaceutical company focused on the treatment of autoimmune diseases potentially mediated by the pathogenic expression of human endogenous retroviral (HERV) genetic elements. The retroviral protein MSRV-Env is ubiquitously expressed in multiple sclerosis (MS) lesions and has been proposed to be a causal trigger underlying MS pathology. GeNeuro is currently evaluating GNbAC1, a neutralizing antibody against MSRV-Env, in a Phase IIb study in collaboration with their partner Servier and expects to report preliminary results in the fourth quarter of 2017. In addition, GeNeuro has a broad portfolio of antibodies to address HERVs that have been linked to other autoimmune diseases.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research